CN101953848A - Medicament for treating cancer and application thereof - Google Patents
Medicament for treating cancer and application thereof Download PDFInfo
- Publication number
- CN101953848A CN101953848A CN 201010524609 CN201010524609A CN101953848A CN 101953848 A CN101953848 A CN 101953848A CN 201010524609 CN201010524609 CN 201010524609 CN 201010524609 A CN201010524609 A CN 201010524609A CN 101953848 A CN101953848 A CN 101953848A
- Authority
- CN
- China
- Prior art keywords
- phosphoric acid
- salt
- medicine
- trivalent
- tetravalence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a medicament for treating cancer and application thereof, which belong to the field of chemical medicaments. The technical problem solved by the invention is to provide the medicament for treating cancer. The medicament for treating cancer comprises the following active components: trivalent V salts of phosphoric acid. Compared with a commercially available similar medicament, the medicament of the invention has an obviously lower cost, thereby reducing the economic burden of a patient. Clinical researches show that the medicament has no obvious side or toxic effect in use, and also cannot increase pain for the body of the patient. The medicament has a higher cure rate, provides a now selection for treating cancer, and has an extensive market prospect.
Description
Technical field
The present invention relates to medicine for the treatment of cancer and uses thereof, belong to the chemical medicine field.
Background technology
Cancer, cerebral thrombosis, diabetes, nervous headache and insomnia are comparatively complicated difficult and complicated illness, and the patient suffers untold misery, and has a strong impact on patient's quality of life.At present the above-mentioned disease of treatment mainly adopt operative treatment and or expectant treatment, but no matter operative treatment and or expectant treatment, except costing an arm and a leg, its cure rate is all on the low side, and some treatment means also can increase the weight of patient's misery.
Vanadium is one of trace element necessary in the human body, and vanadium is extremely low at the intravital content of people, and insufficient total amount is 1 milligram in the body, mainly is distributed in internal organs, positions such as liver, kidney, thyroid especially, and content is also higher in the osseous tissue.Vanadium only is 5% at the gastrointestinal absorbance, and its absorption site is mainly at upper digestive tract.About 95% vanadium combines and carries with transferrins with ionic condition in the blood, so vanadium and ferrum can interact in human body.Vanadium is a many-side in the intravital function of people, and the most approved vanadium lacks the research to goat and white mouse that performance comes from report in 1987, and the goat that vanadium lacks shows the abortion ratio increase and milk yield reduces.In the white mouse experiment, the vanadium shortage causes growth inhibited, and the reproduction function is weak, the ratio increase of thyroid weight and body weight and the variation of plasma thyroid hormones concentration.At present, still indeterminate for the research of human body vanadium deficiency disease.
Heyliger in 1985 etc. find that for the first time vanadate has blood sugar reducing function to the diabetes white mouse, thereafter a series of animal experiment studies of numerous scientists show, vanadium is all effective to insulin dependent diabetes mellitus (IDDM) (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), and is particularly effective to serious insulin resistant type animal.Vanadium has the same effect of insulin in human body, promote lipogenesis, suppresses the effect of decomposing.Its effect is to suppress glycogen heteroplasia enzymatic activity, reduces glyconeogenesis, suppresses the activity of tyrosine phospholipase, and plays the effect of receptor in insulin conducted signal path, thereby reduces hyperglycemia.
Summary of the invention
Technical problem to be solved by this invention provides a kind of medicine for the treatment of cancer.
The medicine that the present invention treats cancer comprises following active component: the trivalent V salt of phosphoric acid.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
Wherein, as optimized technical scheme, the mol ratio of the trivalent V salt of the phosphoric acid in the medicine of above-mentioned treatment cancer and the tetravalence V salt of phosphoric acid is 0.9～1.1: 0.9～1.1.
Wherein, as preferred technical scheme, the mol ratio of the trivalent V salt of the phosphoric acid in the medicine of above-mentioned treatment cancer and the tetravalence V salt of phosphoric acid is 1: 1.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the pentavalent V salt of phosphoric acid; Wherein, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Wherein, the trivalent V salt of above-mentioned phosphoric acid is preferably: VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3The tetravalence V salt of above-mentioned phosphoric acid is preferably: (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The pentavalent V salt of above-mentioned phosphoric acid is preferably VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises an amount of phosphoric acid.When the active component for the treatment of the medicine of cancer as the present invention contained phosphoric acid, it was a solution dosage, the guaranteeing with consumption that the rest activity composition dissolves fully and get final product of phosphoric acid.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the phosphate content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly;
The active component that the present invention treats the medicine of cancer can be only be the trivalent V salt of phosphoric acid.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid and the pentavalent V salt of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt and an amount of phosphoric acid of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Further, the active component that the present invention treats the medicine of cancer can also be the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt of phosphoric acid and an amount of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%; The phosphate content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly.
Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of above-mentioned phosphoric acid and phosphoric acid is preferably 0.9～1.1: 0.9～1.1.The mol ratio of the trivalent V salt of above-mentioned phosphoric acid and the tetravalence V salt of phosphoric acid most preferably is 1: 1.
Wherein, the trivalent V salt of above-mentioned phosphoric acid is preferably: VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3The tetravalence V salt of above-mentioned phosphoric acid is preferably: (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The pentavalent V salt of above-mentioned phosphoric acid is preferably VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Medicine of the present invention can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
The medicine that the present invention treats cancer can be the pharmaceutical dosage form of routine, and wherein, the dosage form that the present invention treats the medicine of cancer is preferably external preparation.Wherein, external preparation is preferably transdermal formulation.Further, described transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
The present invention also provides the medicine of above-mentioned treatment cancer in the purposes that is used for preparing the medicine for the treatment of cancer.
Wherein, the present invention treats the following cancer of medicine preferred therapeutic of cancer: pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
The cost that medicine of the present invention is compared commercially available similar medicine is obviously lower, has alleviated patient's financial burden.Show through clinical research, use medicine of the present invention not see that obvious toxic and side effects is arranged, also can not increase painful to patient body.The cure rate of medicine of the present invention is higher, for treatment for cancer provides a kind of new selection, has vast market prospect.
The specific embodiment
The medicine that the present invention treats cancer comprises following active component: the trivalent V salt of phosphoric acid.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
Wherein, as optimized technical scheme, the mol ratio of the trivalent V salt of the phosphoric acid in the medicine of above-mentioned treatment cancer and the tetravalence V salt of phosphoric acid is 0.9～1.1: 0.9～1.1.
Wherein, as preferred technical scheme, the mol ratio of the trivalent V salt of the phosphoric acid in the medicine of above-mentioned treatment cancer and the tetravalence V salt of phosphoric acid is 1: 1.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the pentavalent V salt of phosphoric acid; Wherein, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Wherein, the trivalent V salt of above-mentioned phosphoric acid is preferably: VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3The tetravalence V salt of above-mentioned phosphoric acid is preferably: (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The pentavalent V salt of above-mentioned phosphoric acid is preferably VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises an amount of phosphoric acid.When the active component for the treatment of the medicine of cancer as the present invention contained phosphoric acid, it was a solution dosage, the guaranteeing with consumption that the rest activity composition dissolves fully and get final product of phosphoric acid.
Further, better for the drug effect that makes medicine of the present invention, the active component that the present invention treats the medicine of cancer also comprises the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the phosphate content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly;
The active component that the present invention treats the medicine of cancer can be only be the trivalent V salt of phosphoric acid.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid and the pentavalent V salt of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Further, the present invention's active component for the treatment of the medicine of cancer can also be the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt and an amount of phosphoric acid of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
Further, the active component that the present invention treats the medicine of cancer can also be the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt of phosphoric acid and an amount of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%; The phosphate content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly.
Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of above-mentioned phosphoric acid and phosphoric acid is preferably 0.9～1.1: 0.9～1.1.The mol ratio of the trivalent V salt of above-mentioned phosphoric acid and the tetravalence V salt of phosphoric acid most preferably is 1: 1.
Wherein, the trivalent V salt of above-mentioned phosphoric acid is preferably: VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3The tetravalence V salt of above-mentioned phosphoric acid is preferably: (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The pentavalent V salt of above-mentioned phosphoric acid is preferably VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
Medicine of the present invention can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
The medicine that the present invention treats cancer can be the pharmaceutical dosage form of routine, and wherein, the dosage form that the present invention treats the medicine of cancer is preferably external preparation.
Discover through the present inventor, when the medicine that the present invention treats cancer is transdermal formulation, its drug effect is preferable, and administration by percutaneous absorption can be avoided contingent first pass effect of hepar of oral administration and gastrointestinal deactivation, reduces the side effect of gastrointestinal administration, prove through clinical research, when the present invention treated the medicine administration by percutaneous absorption of cancer, non-evident effect produced, and the patient can be according to self individual variation, regulate dosage, also can discontinue medication at any time.Therefore, the present invention's dosage form for the treatment of the medicine of cancer is preferably transdermal formulation.Further, described transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
When the dosage form of medicine of the present invention is lotion, when using, the patient medicine of the present invention can be added suitable quantity of water, make the pH value of solution reach the acceptable faintly acid scope of human body, soak then and use, get final product about one soak time 10min, during immersion, the vanadium plasma enters in the body, under physiological condition, element generation redox reaction and potential change, activation of active cell mitogen and adjusting metabolism, and then cholesterol reducing, triglyceride and glucose level, play diuresis and promote uric acid sodium excretion and anticancer effect, reach therapeutic purposes.
The present invention also provides the medicine of above-mentioned treatment cancer in the purposes that is used for preparing the medicine for the treatment of cancer.Wherein, the present invention treats the following cancer of medicine preferred therapeutic of cancer: pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
Below in conjunction with embodiment the specific embodiment of the present invention is further described, does not therefore limit the present invention among the described scope of embodiments.
The preparation of embodiment 1 medicine of the present invention
Medicine according to mol ratio preparation table 1.
The set of dispense of table 1 medicine of the present invention is than (mol ratio)
Pharmaceutical dosage form is a lotion, and adding water during use, to be mixed with pH value be to soak behind 5.6 the solution or clean and use, and soak time is about 10min.
Test example 1 adopts Drug therapy breast carcinoma of the present invention
Patient Liu * *: women, 45 years old.
In January, 2009, lump appearred in right breast, was diagnosed as right mammary gland fibroma through hospital.Adopt medicine of the present invention (medicine of embodiment 1, numbering 1), wiping every day mammary gland tumor 3-4 time, and be mixed with after bath essence cleans treatment February with this medicament, lump obviously dwindles, and continues treatment after 3 months, and lump disappears, and checks confirmation through hospital and fully recovers.
Test example 2 adopts the Drug therapy esophageal carcinoma of the present invention
The patient surplus white * *: woman, 50 years old
Chest pain occurs in January, 2008, breathe hard, beat every, the symptom of choking of having a back ache, take food, be diagnosed as the esophageal carcinoma through hospital in February, 2008.
Use medicine of the present invention (medicine of embodiment 1, numbering 2) to be mixed with bath essence and clean treatment after 2 months, spirit is got better, and acataposis subtracts greatly.The check of X line, barium meal is by better; Continue treatment after 1 month, the state of an illness is stable day by day.Do the check of X line barium meal; Focus does not have development.
Test example 3 adopts Drug therapy hepatocarcinoma of the present invention
The patient opens * *: women, 40 years old.
Be diagnosed as uterus carcinoma late period through hospital in January, 2009, and companion's bloody purulent stool is day and night surplus in the of 30 time, once at tumour hospital's chemicotherapy.Symptom is: gastral cavilty aches, detests greasy, belch, pantothenic acid, is afraid of cold, bitter taste, xerostomia, dizziness, dispute such as showing tremendous enthusiasmly scald, stool band pus and blood.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 7) to be mixed with bath essence and clean treatment after 3 months, the check Uterine mucosa is smooth through the man hospital of number, and pathology confirms to fully recover.
Test example 4 adopts Drug therapy pulmonary carcinoma of the present invention
Patient Wu * *, the male 45 years old, has the long-term smoking history.
In November, 2007, cough appearred in the patient, and sputum mixed with blood is diagnosed as pulmonary carcinoma late period through examination in hospital.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 11) to be mixed with bath essence, 4 scourings every day.After 1 month, patient's minimizing of coughing, no sputum mixed with blood situation occurs.Continue to strengthen treatment 3 months, the patient no longer coughs, and through hospital's check, it is normal that health is recovered substantially.
Test example 5 adopts Drug therapy leukemia of the present invention
The patient opens * *, women, 50 years old.
Be diagnosed as acute leukemia M3 through examination in hospital in August, 2009.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 10) to be mixed with bath essence, 5 scourings every day.After 1 month, check bone marrow, report bone marrow is alleviated fully, continues to strengthen treatment 6 months, check bone marrow, report bone marrow recovers normal level.
Claims (18)
1. the medicine of treatment cancer is characterized in that comprising following active component: the trivalent V salt of phosphoric acid.
2. the medicine of treatment cancer according to claim 1 is characterized in that its active component also comprises the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
3. the medicine of treatment cancer according to claim 1 and 2 is characterized in that its active component also comprises the pentavalent V salt of phosphoric acid; Wherein, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
4. according to the medicine of each described treatment cancer of claim 1～3, it is characterized in that: described active component also comprises an amount of phosphoric acid.
5. the medicine of treatment cancer according to claim 4 is characterized in that: described active component also comprises the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the phosphate content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly.
6. the medicine of treatment cancer according to claim 1 is characterized in that its active component is the trivalent V salt of phosphoric acid.
7. the medicine of treatment cancer according to claim 1 is characterized in that its active component is the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid; Wherein, the mol ratio of the tetravalence V salt of the trivalent V salt of phosphoric acid and phosphoric acid is 0.5～1.5: 0.5～1.5.
8. the medicine of treatment cancer according to claim 1 is characterized in that its active component is the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid and the pentavalent V salt of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
9. the medicine of treatment cancer according to claim 1 is characterized in that its active component is the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt and an amount of phosphoric acid of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%.
10. the medicine of treatment cancer according to claim 1 is characterized in that its active component is the phosphate of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the trivalent V salt of phosphoric acid, the tetravalence V salt of phosphoric acid, the pentavalent V salt of phosphoric acid and an amount of phosphoric acid; Wherein, the mol ratio of the trivalent V salt of phosphoric acid and the tetravalence V salt of phosphoric acid is 0.5～1.5: 0.5～1.5, the content of the pentavalent V salt of phosphoric acid be the trivalent V salt of phosphoric acid and phosphoric acid tetravalence V salt integral molar quantity 0.5%～5%; The phosphate content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively phosphoric acid V salt integral molar quantity 10
-6～10
-3Doubly.
11. the medicine according to claim 2,3,4,5,7,8,9 or 10 described treatment cancers is characterized in that: the mol ratio of the trivalent V salt of described phosphoric acid and the tetravalence V salt of phosphoric acid is 0.9～1.1: 0.9～1.1.
12. the medicine of treatment cancer according to claim 11 is characterized in that: the mol ratio of the trivalent V salt of described phosphoric acid and the tetravalence V salt of phosphoric acid is 1: 1.
13. the medicine according to each described treatment cancer of claim 1～12 is characterized in that: the trivalent V salt of described phosphoric acid is: VPO
4, V
2(HPO
4)
3Or V (H
2PO
4)
3The tetravalence V salt of described phosphoric acid is: (VO)
3(PO
4)
2, VOHPO
4Or VO (H
2PO
4)
2The pentavalent V salt of described phosphoric acid is VOPO
4, (VO)
2(HPO
4)
3Or VO (H
2PO
4)
3
14. the medicine according to each described treatment cancer of claim 1～13 is characterized in that: the dosage form external preparation of the medicine of described treatment cancer.
15. the medicine of treatment cancer according to claim 14 is characterized in that: the dosage form transdermal formulation of the medicine of described treatment cancer.
16. the medicine of treatment cancer according to claim 15 is characterized in that: described transdermal formulation is patch, varnish, liniment, aerosol, unguentum or lotion.
17. the medicine of each described treatment cancer of claim 1～16 is in the purposes that is used for preparing the medicine for the treatment of cancer.
18. purposes according to claim 17 is characterized in that: described cancer is pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010524609A CN101953848B (en) | 2010-10-29 | 2010-10-29 | Medicament for treating cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010524609A CN101953848B (en) | 2010-10-29 | 2010-10-29 | Medicament for treating cancer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101953848A true CN101953848A (en) | 2011-01-26 |
| CN101953848B CN101953848B (en) | 2011-12-21 |
Family
ID=43481606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010524609A Active CN101953848B (en) | 2010-10-29 | 2010-10-29 | Medicament for treating cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101953848B (en) |
-
2010
- 2010-10-29 CN CN201010524609A patent/CN101953848B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 《中国药物与临床》 20061130 张玲 《钒的医学应用研究进展》 844 第6卷, 第11期 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101953848B (en) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101961347B (en) | Medicinal composition for treating cancer and use thereof | |
| CN102836419A (en) | Iron protein succinylate oral solution and preparation method thereof | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| CN101953848B (en) | Medicament for treating cancer and application thereof | |
| CN104256651B (en) | Improve composition and method of making the same and the application of male's sexual | |
| CN102366501B (en) | Self-heated traditional Chinese medicine (TCM) emplastrum for improving sleep quality | |
| AU2003285351B2 (en) | Agent having a destructive effect on malignant tumors and method for the production thereof | |
| CN101129956A (en) | Traditional Chinese medicine for treating rickets | |
| CN101972273B (en) | Application of medicine in preparing medicines for treating diabetes mellitus | |
| CN106580938A (en) | Tromethamine organic acid salt, and preparation method and application thereof | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN100364527C (en) | Composition of vitamin C and arginine and its application | |
| CN103599254A (en) | Chinese medicinal composition for diabetes | |
| Hutchison | The elements of medical treatment | |
| CN101347483A (en) | Chinese herbal medicinal composition for treating enterogastric disease and preparation method and use | |
| CN105878365A (en) | Anticancer drug and preparation method thereof | |
| CN110302266A (en) | A kind of hypoglycemic composition and preparation method thereof | |
| JP2007031282A (en) | Vanadium ion-containing sugar, lipid and/or nitrogen metabolic disease-improving agent | |
| HOLMES | VIBURNUM PRUNIFOLIUM. Read in the Section on Materia Medica and Pharmacy, at the Forty-fifth Annual Meeting of the American Medical Association, held at San Francisco, June 5-8, 1894. | |
| CN102526273A (en) | Composition for treating functional dyspepsia and preparation method thereof | |
| Hurd | Consumption in New England | |
| CN105078950A (en) | Composite preparation containing zinc, magnesium and calcium ions and preparing method of composite preparation | |
| CN101390968A (en) | Chinese herbal medicine composition for treating intestinal tract disease and preparation method and use thereof | |
| CN108096366A (en) | A kind of hypoglycemic biomass formula | |
| CN106474335A (en) | A kind of treat Chinese medicine composition of canker sore as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |